Nk T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Nk T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating tislelizumab plus zeprumetostat for relapsed or refractory NK/T-cell lymphoma is listed as not yet rec…
-
CLINICAL_TRIALS research · 2025-12-11Clinical Trial Update: Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma [Phase 2]
Phase 2 trial evaluating conditioning with thiotepa, cyclophosphamide, and busulfan before allogeneic hematopoietic stem cell transplantatio…
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types [Phase 2]
Phase 2 trial update indicating access to pembrolizumab for selected rare cancer types has been secured.
-
CLINICAL_TRIALS trial_result · 2022-04-07Clinical Trial Update: Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma [Phase 2]
Phase 2 trial update evaluating BV in combination with tislelizumab for CD30+ relapsed/refractory NK/T-cell lymphoma, focusing on efficacy a…
-
CLINICAL_TRIALS trial_result · 2020-08-18Clinical Trial Update: Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas [Phase 1]
Phase 1 trial evaluating siplizumab with dose-adjusted EPOCH-Rituximab in T- and NK-cell lymphomas has completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-07-29Clinical Trial Update: A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma [Phase 4]
A Phase 4 clinical trial investigating chidamide combined with etoposide in relapsed or refractory NK/T-cell lymphoma; current status is unk…
-
CLINICAL_TRIALS trial_result · 2020-07-07Clinical Trial Update: Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma [Phase 2]
Phase 2 trial evaluating anti-PD-1 antibody in combination with peg-asparaginase and chidamide for early-stage NK/T-cell lymphoma; status cu…
-
CLINICAL_TRIALS trial_result · 2020-05-07Clinical Trial Update: Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating lenalidomide with sintilimab for relapsed/refractory NK/T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2018-12-14Clinical Trial Update: A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma [Phase 2]
Phase 2 clinical trial update for liposome-entrapped mitoxantrone hydrochloride injection in relapsed/refractory peripheral T-cell lymphoma …
-
CLINICAL_TRIALS trial_result · 2018-10-09Clinical Trial Update: PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating PD-1 blockade combined with Apatinib in relapsed or refractory NK/T-cell lymphoma.